Dr. Eynott leads Acudora in strategy, fund raising and partnering based on his significant experience in partnering and innovation in his current position in charge of Technology Transfer Licenses at the University of Arizona and former position in North America for the SANOFI R&D group. Paul received a PhD in pharmacology from the National Heart and Lung Institute, Imperial College London and received a BS (with honors) in pharmacology.

Dr. McClain is the Inventor of Acudora's core technology. An internationally recognized physicist with a 40+ year career, he has been instrumental in pioneering work in astronomy, computer architecture, system software design and signal processing. David studied physics and astronomy at Rose-Hulman Institute of Technology, completed his graduate studies in theoretical physics at The City College of NY and his doctoral studies in observational inf

Mr. Nguyen manages Acudora's intellectual properties. He has extensive experience in developing strategic patent portfolios for start­‐ups, including Acudora. In addition to his role as Vice President of Business Development, Quan is also Acudora's outside patent attorney and is a shareholder at Nguyen & Tarbet, LLC. He received a BS from UC, Irvine, master’s degree from UC, Los Angeles and a Juris Doctorate from Southwestern University School of

Mr. Cohen provides Acudora with financial leadership. He is currently a shareholder and Executive VP of Beach Fleischman & Company, PC with areas of expertise including business consulting, retirement planning, tax planning and strategy. David is a member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants. He earned his BA degree in business administration from the University of Arizo

Mr. Masson is responsible for developing business plans, budgeting, and managing our resources. He has extensive experience as a product development specialist for small and emerging technology companies and more recently led the development and implementation of the first enterprise-­‐level mobile application at the UA, where he earned his MBA from the McGuire Center for Entrepreneurship in the Eller College of Management.

Mr. Richied has worked in IPO investment banking, biotech venture capital, and was CEO of EnzyMed, a successful biotech company acquired by Albany Molecular. Most recently, he worked in the finance department of the Burnham Institute for Medical Research in La Jolla, CA. Chris received an MBA from Harvard Business School, MS in Management Information Systems from the University of Arizona, and BS in Chemical Engineering from Ohio State University